GenSpera combines its novel biomedical technology platform with powerful insight and rigorous scientific methods to develop targeted treatments with fewer side-effects

  • Phase II clinical trials for lead compound for mipsagargin, also known as G-202, are underway in two indications:
    • Hepatocellular carcinoma, or liver cancer
    • Glioblastoma, or brain cancer
  • Experienced and motivated team drives the process:
    • Core team has extensive experience in successfully identifying and bringing oncology treatments to the clinic
    • Scientific Advisory Board is comprised of leading researchers who are both the inventors of the technology and founders
  • Technology platform supports the development of a suite of drugs targeted at different cancers, as well as other applications such as imaging
  • Over 15 years of research at Johns Hopkins Medical Center and other renowned research centers, including the University of Copenhagen:
    • Strong intellectual property portfolio
    • No milestones or royalty payments owed to third parties
  • Leverage the team's passion and expertise in identifying promising treatments and bringing them to the clinic